Artelo Biosciences Names Mark Spring Chief Financial Officer

*SOLANA BEACH, Calif.* — Artelo Biosciences Inc. appointed Mark Spring,
CPA, Chief Financial Officer, effective November 1. Spring had been serving
as a financial consultant to the company since December 2024. The
appointment strengthens Artelo’s financial leadership as it advances its
clinical pipeline and corporate growth initiatives.

Spring brings 30 years of experience in life sciences to his role,
including financial leadership of private and public, domestic and
multinational, commercial and development-stage companies. He recently
served as interim CFO for LENZ Therapeutics through its reverse merger
transaction and was co-founder and CFO of Secura Bio, a commercial-stage
oncology therapeutics company. He also served as CFO for Hyperion
Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless, and
Genoptix. Spring has extensive M&A and licensing experience with
significant roles in major transactions at Caremark, Dade Behring, Baxter,
MedImmune, Prometheus, and Genoptix. He holds a BA in Business
Administration from Monmouth College, completed postgraduate studies at the
University of Texas at Dallas, and is a Certified Public Accountant
(active).